Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

- (2012) Volume 4, Issue 2

Hyperhomocysteinemia and Cardiovascular Disease: A Transitory Glance

Rohilla Ankur1*, Dhama Pooja1, Rohilla Seema2, Dahiya Amarjeet1, Kushnoor Ashok1
  1. Department of Pharmaceutical Sciences, Shri Gopi Chand Group of Institutions, Baghpat-250609, UP, India
  2. Department of Pharmaceutical Sciences, Hindu College of Pharmacy, Sonepat 131001, Haryana, India
Corresponding Author:Ankur Rohilla M.Pharm, Senior Lecturer, Department of Pharmaceutical Sciences, Shri Gopi Chand Group of Institutions, Baghpat-250609, UP, India E-mail: ankurrohilla1984@gmail.com
Received:16 April 2012 Accepted: 11 May 2012
Citation: Rohilla Ankur*, Dhama Pooja, Rohilla Seema, Dahiya Amarjeet, Kushnoor Ashok “Hyperhomocysteinemia and Cardiovascular Disease: A Transitory Glance”, Int. J. Drug Dev. & Res., April-June 2012, 4(2): 70-75. doi: doi number
Copyright: © 2010 IJDDR, Rohilla Ankur et al. This is an open access paper distributed under the copyright agreement with Serials Publication, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Related article at Pubmed, Scholar Google
Visit for more related articles at International Journal of Drug Development and Research

Abstract

Hyperhomocysteinemia (Hhcy) is a medical condition characterized by abnormally large levels of homocysteine in blood. The involvement of homocysteine (Hcy) in various biochemical reactions causes deficiencies of the vitamins like pyridoxine (B6), folic acid (B9), or B12 leading to higher Hcy levels. Hhcy has been considered as an independent risk factor for various cardiovascular diseases like endothelial dysfunction, vascular inflammation, atherosclerosis, hypertension, cardiac hypertrophy and heart failure. The review article critically explains about the mechanisms involved in the Hhcy-induced development and progression of various cardiovascular disorders

Keywords

Hyperhomocysteinemia, Homocysteine, Cardiovascular

INTRODUCTION

Hcy is a highly reactive sulphur-containing amino acid derived from methionine, an essential amino acid, which is the solitary resource of Hcy [1, 2, 3]. When excess Hcy is produced in the body and not readily converted into methionine or cysteine, it is excreted out of the tightly regulated cell environment into the blood. It is the role of the liver and kidney to remove excess Hcy from the blood. In many individuals with inborn errors of Hcy metabolism, kidney or liver disease, nutrient deficiencies, Hcy levels rise beyond normal levels lead to Hhcy [4]. Thus, Hhcy can be defined as a pathological condition characterized by an increase in plasma concentration of total Hcy [4, 5, 6]. Hhcy increases the generation of ROS by activating NADPH oxidase, downregulates the endothelial nitric oxide synthase (eNOS) and thus reduces the bioavailability of nitric oxide
(NO) [7, 8, 9, 10]. Moreover, Hhcy has been noted to increase the production of proinflammatory cytokines like tumor necrosis factor-A (TNF-A) by activating nuclear factor-kappa B (NF-CB) [11]. The elevated homocysteine concentration is an independent risk factor for various cardiovascular disorders [12, 13]. Hhcy is associated with an increased risk of cardiovascular complications such as atherosclerosis, endothelial dysfunction, hypertension, myocardial infarction and chronic heart failure (CHF) [7, 8, 13, 14, 15, 16, 17]. The review decisively explains about the correlation between excess Hcy concentration and cardiovascular disorders.

SYNTHESIS AND METABOLISM OF HCY

Hcy is a sulphur containing amino acid which is generated from the metabolism of methionine, the synthesis and metabolism of which involves four steps (Fig 1). The first step is transmethylation pathway which involves the conversion of methionine to homocysteine [18]. Second step is the transsulphuration pathway that involves the irreversible conversion of homocysteine to cysteine in presence of cystathione-b-synthase (CBS), a rate limiting enzyme and vitamin B6, an essential cofactor [19, 20]. The third step is the re-methylation pathway during which the regeneration of methionine from homocysteine occurs that is mediated by methionine synthase alongwith 5,10-methylenetetrahydrofolate (MTHF) and Vitamin B12 as essential cofactors. The last step is the regeneration of methylenetetrahydrofolate (MTHF) from tetrahydrofolate (THF) which is catabolized by enzyme 5,10-methelene-tetrahydrofolate reductase [10, 13].

HHCY AND CARDIOVASULAR DISORDERS: AN OVERVIEW

Epidemiological evidences and observational studies data suggest an association between elevated Hcy levels and increased risk of cardiovascular complications like atherosclerosis, endothelial dysfunction, hypertension, myocardial infarction and chronic heart failure [7, 8, 13, 14, 15, 16, 17]. Atherosclerosis is characterized by a thickening of the arterial wall due to smooth muscle cell proliferation, lipid deposits and fibrosis [21, 22]. The rupture of lipidcontaining atherosclerotic plaques results in thrombosis that further leads to myocardial infarction and stroke [21]. Moreover, Hhcy has been found to be associated with primary thrombotic disorder affecting arteries and veins [23]. In addition, Hhcy has been noted to be associated with a factor or factors that primarily cause venous and arterial thrombosis. It has also been reported that very high homocysteine concentrations are thrombogenic. It was evident that in patients presented with cystathionine-F-synthase (CBS) deficiency and inborn errors of homocysteine remethylation, the accumulation of the precursor of homocysteine, Sadenosylhomocysteine (SAH), occurs that ultimately leads to hypomethylation of some essential components [10, 24]. The role of SAH in Hhcy condition was evidenced by the fact that the therapy which lowers plasma homocysteine concentration also reduced SAH and restored impaired transmethylation reactions. The well reported common causes of Hhcy may be attributed to low serum or red cell folate concentrations, vitamin B-12 deficiency, decline in renal function and the TT genotype for the common C677T/MTHFR polymorphism alongwith low folate status [25, 26, 27, 28]. Further, the interrelations between endotheliumdependant vasodilatation mediated by NO release and plasma homocysteine have been established [29, 30]. It has been shown that that endotheliumdependant vasodilatation is reduced in Hhcy patients but not in their obligate heterozygote parents evidencing the probable role of Hhcy in the development and progression of endothelium dysfunction. Additionally, several groups established 3-fold increase in circulating homocysteine after a standard methionine load diet that reduced endothelium-dependant vasodilatation [31]. In another study, it was demonstrated that treatment with oral ascorbic acid, a potent antioxidant, prevented endothelial dysfunction associated with a 2-3-fold increase in homocysteine after a standard methionine load [22, 32]. The vascular risk associated with Hhcy has been observed to be stronger in hypertensive individuals [3, 33, 34]. Hence, the attention has been focused on the direct relations of plasma homocysteine to blood pressure and hypertension because it has been suggested that the adverse risk associated with Hhcy is mediated in part by the positive association of homocysteine with hypertension [35, 36]. In the third National Health and Nutrition Examination Survey (NHANES III), it was observed that persons with higher plasma homocysteine concentrations showed a 2-3-fold increase in the prevalence of hypertension when compared to persons with normal homocysteine levels [35, 37]. Additionally, a potential role of homocysteine in the pathogenesis of hypertension was evidenced by the fact that homocysteinelowering treatment reduced systolic and diastolic blood pressures [38]. Thus, a considerable body of evidence suggests a role for plasma homocysteine in the pathogenesis of hypertension [34, 36, 39]. Furthermore, plasma homocysteine has been suggested to be increased in CHF patients and hence, represents a newly recognized risk marker [40, 41, 42]. The data from clinical studies indicate that Hhcy is associated with an increased incidence of CHF as well as with the severity of the disease [43, 44, 45, 46]. The results from various studies show that Hhcy causes adverse cardiac remodeling characterized by interstitial and perivascular fibrosis resulting in increased myocardial stiffness [47]. It has been noted that Hhcy affects the pump function of the myocardium, the underlying mechanism of which potentially involves the direct effects of homocysteine on the myocardium as well as NO independent vascular effects [16, 47]. In addition, it has been also suggested that Hhcy derived endothelial dysfunction induced an increased expression of adhesion molecules followed by immigration and activation of inflammatory cells, secretion of chemokines, altered fibroblast and cardiomyocyte function and an increased collagen synthesis that has been ultimately lead to CHF [48, 49, 50].

CONCLUSION

The impaired metabolism of Hcy in blood produces the Hhcy which has been regarded as an independent risk factor for many cardiovascular diseases as it exerts negative role on endothelial membrane. However, many studies have reported a significant correlation between Hhcy and cardiovascular complications but data from ongoing studies are awaited to clarify this issue further. Hence, new studies are demanded in order to provide the evidence of involvement of potent signaling markers in Hhcy-induced cardiovascular complications and new therapies to relieve this condition.

Figures at a glance

Figure 1
Figure 1
 
5002

References

  1. Chambers JC, Seddon MDI, Shah S, Kooner JS.Homocysteine-a novel risk factor for vascular disease. J R Soc Med, 2001; 94: 10-13.
  2. Mangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future
  3. Cheng S, Feng J, Wang X. Research advances in the treatment of hyperhomocysteinemia. Sheng Li Ke
  4. Marosi K, Agota A, Vegh V, Joo JG, Langmar Z,Kriszbacher I, et al. The role of homocysteine and
  5. methylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductasepolymorphisms in the development ofcardiovascular diseases and hypertension. Orv Hetil2012; 153: 445-453.
  6. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E,Reitsma PH, et al. Hyperhomocysteinemia as a riskfactor for deep-vein thrombosis. N Engl J Med,1996; 334: 759-762.
  7. Ueland PM, Refsum H, Beresford SAA, Vollset SE.The controversy over homocysteine and
  8. Austin R, Lentz S, Werstuck G. Role of hyperhomocysteinemia in endothelial dysfunction and
  9. Tyagi N, Sedoris KC, Steed M, Ovechkin AV, MoshalKS, Tyagi SC. Mechanisms of
  10. homocysteineinducedoxidative stress. Am J Physiol Heart Circ Physiol, 2005; 289: H2649-H2656.
  11. Suemastu N, Ojaimi C, Kinugawa S, Wang Z, Xu X,Koller A, et al. Hyperhomocysteinemia alters
  12. cardiac subustrate metabolism by impairing nitricoxide bioavailability through oxidative stress.
  13. Hoffman M. Hypothesis: hyperhomocysteinemia is an indicator of oxidant stress. Med Hypotheses,
  14. Bai YP, Liu YH, Chen J, Song T, You Y, Tang ZY, etal. Rosiglitazone attenuates NF- kB dependent
  15. ICAM-1 and TNF-alpha production caused byhomocysteine via inhibiting ERK1/2/p38MAPK activation. Biochem Biophys Res Commun, 2007;360: 20-26.
  16. Bostom AG, Silbershatz H, Rosenberg IH.Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality inelderly Framingham men and women. Arch Intern Med, 1999; 159: 1077-1080.
  17. Balakumar P, Singh AP, Ganti GS, Singh M.Hyperhomocysteinemia and cardiovascular disorders: Is there a correlation? Trends Med Res,2007; 2: 160-6.
  18. Nygard O, Vollset SE, Refsum H. Total homocysteine and cardiovascular risk profile. JAMA, 1995;
  19. Helfenstein T, Fonseca FAH, Relvas WGM, SantosAO, Dabela ML, Matheus SCP, et al. Prevalence ofmyocardial infarction is related to hyperhomocysteinemia but not influenced by C677T
  20. methylenetetrahydrofolate reductase and A2756Gmethionine synthase polymorphisms in diabetic
  21. Herrmann M, Kindermann I, Muller S, Georg T, Kindermann M, Bohm M, et al. Relationship of
  22. plasma homocysteine with the severity of chronic heart failure. Clin Chem, 2005; 51: 1512-1515.
  23. Ntaios G, Savopoulos C, Chatzopoulos S,  Mikhailidis D, Hatzitolios A. Iatrogenic
  24. hyperhomocysteinemia in patients with metabolicsyndrome: a systematic review and metaanalysis.
  25. Prasad K. Homocysteine, a Risk Factor for Cardiovascular Disease. Int J Angiol 1999; 8: 76-86.
  26. Durand PM, Prost N, Loreau S, Lussier C, Blache D.Impaired homocysteine metabolism and
  27. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White
  28. Brattstrom L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin
  29. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine betasynthase deficiency. Am J Hum Genet, 1985; 37: 1-31.
  30. Langman LJ, Cole DE. Homocysteine. Crit Rev Clin Lab Sci, 1999; 36: 365-406.
  31. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, Lindenbaum J. Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas
  32. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H. The effect of reduced glomerular filtration rate
  33. on plasma total homocysteine concentration. ScandJ Clin Lab Invest, 1996; 56: 41-46.
  34. Brattstrom L, Wilcken DE, Ohrvik J, Brudin L.Common methylenetetrahydrofolate reductase gene
  35. mutation leads to hyperhomocysteinemia but not tovascular disease: the result of a meta-analysis.
  36. Guthikonda S, Haynes WG. Homocysteine: role andimplications in atherosclerosis. Curr Atheroscler
  37. Cheng Z, Jiang X, Kruger WD, Praticò D, Gupta S,Mallilankaraman K, et al. Hyperhomocysteinemia
  38. impairs endothelium-derived hyperpolarizingfactor-mediated vasorelaxation in transgenic cystathionine beta synthase-deficient mice. Blood,2011b; 118: 1998-2006.
  39. Kietadisorn R, Kietselaer BL, Schmidt HH, MoensAL. Role of tetrahydrobiopterin (BH4) in
  40. hyperhomocysteinemia-induced endothelialdysfuction: new indication for this orphan-drug?Am J Physiol Endocrinol Metab, 2011; 300: E1176.
  41. Celermajer DS, Sorensen K, Ryalls M, Robinson J,Thomas O, Leonard JV, et al. Impaired endothelial
  42. function occurs in the systemic arteries of childrenwith homozygous homocystinuria but not in their
  43. Kanani PM, Sinkey CA, Browning RL, Allaman M,Knapp HR, Haynes WG. Role of oxidant stress in
  44. endothelial dysfunction produced by experimental hyperhomocysteinemia in humans. Circulation,
  45. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma
  46. homocysteine as a risk factor for vascular disease:the European Concerted Action Project. JAMA,1997; 277: 1775-1781.
  47. Sundstrom J, Sullivan L, D'Agostino RB, JacquesPF, Selhub J, Rosenberg IH, et al. Plasma
  48. homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study.
  49. Lim U, Cassano PA. Homocysteine and blood pressure in the Third National Health and Nutrition
  50. van Guldener C, Nanayakkara PW, Stehouwer CD.Homocysteine and blood pressure. Curr Hypertens
  51. Pierdomenico SD, Bucci A, Lapenna D, Lattanzio FM, Talone L, Cuccurullo F, et al. Circulating
  52. homocysteine levels in sustained and white coat hypertension. J Hum Hypertens, 2003; 17: 165-170.
  53. Mangoni AA, Sherwood RA, Swift CG, Jackson SH. Folic acid enhances endothelial function and
  54. reduces blood pressure in smokers: a randomized controlled trial. J Intern Med, 2002; 252: 497-503.
  55. Marosi K, Agota A, Végh V, Joó JG, Langmár Z,Kriszbacher I, et al. The role of homocysteine andmethylenetetrahydrofolate reductase, methionine synthase, methionine synthase reductase
  56. polymorphisms in the development ofcardiovascular diseases and hypertension. Orv
  57. Sundstrom J, Vasan RS. Homocysteine and heart failure: a review of investigations from the
  58. Vizzardi E, Bonadei I, Zanini G, Fiorina C, Raddino R, Dei Cas L. Homocysteine: a casual link with heartfailure?. Minerva Med, 2009; 100: 421-427.
  59. Alter P, Rupp H, Rominger MB, Figiel JH, Renz H,Klose KJ, et al. Association of
  60. hyperhomocysteinemia with left ventriculardilatation and mass in human heart. Clin Chem Lab Med, 2010; 48: 555-560.
  61. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev, 2000; 5: 167-173.
  62. Lloyd-Jones DM. The risk of congestive heartfailure: sobering lessons from the Framingham
  63. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ,D'Agostino RB, Jacques PF, et al. Relations of
  64. plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur
  65. Agoston-Coldea L, Mocan T, Gatfosse M, Lupu S,Dumitrascu DL. Plasma homocysteine and the
  66. severity of heart failure in patients with previous myocardial infarction. Cardiol J, 2011; 18: 55-62.
  67. Herrmann M, Taban-Shomal O, Hubner U, BohmM, Herrmann W. A review of homocysteine and
  68. Joseph J, Washington A, Joseph L, Koehler L, FinkLM, Hauer-Jensen M, et al.
  69. Hyperhomocysteinemialeads to adverse cardiac remodeling in hypertensiverats. Am J Physiol Heart Circ Physiol, 2002; 283:H2567-H2574.
  70. Agoston-Coldea L, Mocan T, Gatfosse M, Lupu S,Dumitrascu DL. Plasma homocysteine and the
  71. severity of heart failure in patients with previous myocardial infarction. Cardiol J, 2011; 18: 55-62.
  72. Givvimani S, Qipshidze N, Tyagi N, Mishra PK, SenU, Tyagi SC.Synergism between arrhythmia andhyperhomo-cysteinemia in structural heart disease.Int J Physiol Pathophysiol Pharmacol 2011; 3: 107-